One Eleven Interactive, Inc

Innovative marketing programs for the pharmaceutical industry

One Eleven Interactive, Inc Introduction Why Teva Pharmaceuticals stock is up as the Zika virus threat grows

Why Teva Pharmaceuticals stock is up as the Zika virus threat grows



Teva, the makers of the vaccine, is up 1% after the company said it will begin offering a free Zika trial to women who have received the vaccine for the first time. 

“This is an exciting time for our company and our community,” the company tweeted.

“We are excited to expand the availability of the Zika vaccine and to continue our work with our partners to protect the health and well-being of women in the Americas.”

The company said in a statement that it will offer the trial to the Zika-endemic countries of Brazil, Colombia, El Salvador, Guatemala, Mexico, Nicaragua, Panama, Peru and Venezuela in 2018.

It will also expand the trial by targeting low-income communities.

The vaccine is part of Teva’s effort to reach people who are most at risk of contracting the virus, and the company is hoping that the trial will be the first step toward reaching all women in those countries.

In a statement, Teva said that it was the first vaccine company to deliver to low- and middle-income countries, where it says the virus is concentrated.

“The availability of Zika vaccines and other preventive health measures has proven to be effective in curbing the spread of the virus,” the statement read.

“However, the Zika epidemic is still alive and well in these countries, and we cannot and will not ignore the need to ensure that every single person is protected.”

Teva, which was founded in 1984 and has more than $100 billion in revenue, said it was “deeply grateful” to its partners, including Pfizer and GlaxoSmithKline, who made the vaccine available in 2018 and also said it plans to offer it to other countries as well.

TopBack to Top